Hypermarcas (OTCMKTS:HYPMY) Stock Breaks Below Two Hundred Day Moving Average - Should You Sell?

Key Points

• Hypermarcas shares fell below their 200-day moving average, trading as low as $3.39 versus the $4.44 average, and were last at $3.95. The stock is down 26.9%.
• Analyst sentiment remains generally positive: Jefferies upgraded the stock to “strong buy,” while coverage consists of one Strong Buy and one Hold, producing an overall “Buy” rating.
• The company exceeded quarterly earnings expectations, reporting $0.14 EPS versus the $0.13 consensus estimate. Hypermarcas posted a 19.77% net margin and analysts expect $0.51 EPS for the full fiscal year.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $4.44 and traded as low as $3.39. Hypermarcas shares last traded at $3.95, with a volume of 67,913 shares trading hands.

Analysts Set New Price Targets

Separately, Jefferies Financial Group raised Hypermarcas to a "strong-buy" rating in a report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy".

Hypermarcas Stock Down 26.9%

The firm's 50-day simple moving average is $4.67 and its two-hundred day simple moving average is $4.44. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.86 and a quick ratio of 1.26. The company has a market capitalization of $2.78 billion, a price-to-earnings ratio of 7.90 and a beta of 0.65.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. Sell-side analysts predict that Hypermarcas will post 0.51 EPS for the current fiscal year.

Hypermarcas Company Profile

Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.

Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.

The company's principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.